Clinical Trial Update: BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) [Phase 1, Phase 2]

View source ↗

Summary

This trial investigates BI-1808 as a single agent and in combination with pembrolizumab (Keytruda) for advanced malignancies, including ovarian cancer, T-cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Ovarian Cancer
• T-cell Lymphoma

Drugs mentioned

• BI-1808
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: BioInvent International AB | Conditions: Advanced Malignancies, Ovarian Cancer | Phase 1, Phase 2 | Status: RECRUITING